FIELD: medicine.
SUBSTANCE: claimed invention provides a method for predicting a response of triple negative mammary gland cancer to therapy with an anti-tumour medication. The method includes (a) lysing tumour cells, sampled from the triple negative mammary gland cancer to obtain a cell extract; (b) determining the level of VEGFR2 expression in the cell extract; and (c) comparison of the level of VEGFR2 expression in the cell extract, obtained at stage (b), with the standard level of VEGFR2 expression.
EFFECT: presence of a low level of VEGFR2 expression predicts the response to therapy with an anti-tumour medication, where the anti-tumour medication represents a combination of bevacizumab (Avastin®), carboplatin and paclitaxel.
16 cl, 14 dwg, 7 ex
